Dr. Gregory S. Day
Prior to joining the Knight Alzheimer Disease Research Center as a post-doctoral fellow, Dr. Gregory Day completed his post-graduate training as a Neurology resident at the University of Toronto. Early in the course of his residency Dr. Day learned to apply his medical knowledge and experience to evaluate patients with cognitive impairment. Subsequently, Dr. Day chose to pursue clinical research focused on adapting available clinical tools and technologies to enhance diagnostic accuracy and predict outcomes in patients with dementia. He is currently the recipient of the “Future Leader in Dementia Award”, and the “André Barbea Memorial Prize” for his project investigating the pathological underpinnings of a rare form of autoimmune-mediated encephalopathy.
As the recipient of the 2015 Eugene M Johnson, Jr. Weston Brain Institute Postdoctoral Fellowship Dr. Day is currently working under the mentorship of Dr. John Morris. His current research aims to identify measures that characterize the clinical features associated with rates of progression in a large cohort of dementia patients. Previous studies considering rates of progression have focused predominantly on rapidly progressive dementia due to prion diseases. The RaPID Study will further previous research by considering rates of progression in participants recruited from an academic center focused on the diagnosis and management of several types of age-associated neurodegenerative dementing diseases. This study will provide important information concerning the factors that influence rates of progression in all forms of dementia.